These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30843283)

  • 1. Use of new and uncommon synthetic psychoactive drugs among a nationally representative sample in the United States, 2005-2017.
    Palamar JJ; Le A
    Hum Psychopharmacol; 2019 Mar; 34(2):e2690. PubMed ID: 30843283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting.
    Palamar JJ; Martins SS; Su MK; Ompad DC
    Drug Alcohol Depend; 2015 Nov; 156():112-119. PubMed ID: 26377051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic cathinone adulteration of illegal drugs.
    Oliver CF; Palamar JJ; Salomone A; Simmons SJ; Philogene-Khalid HL; Stokes-McCloskey N; Rawls SM
    Psychopharmacology (Berl); 2019 Mar; 236(3):869-879. PubMed ID: 30338489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-reported use of novel psychoactive substances among attendees of electronic dance music venues.
    Palamar JJ; Acosta P; Sherman S; Ompad DC; Cleland CM
    Am J Drug Alcohol Abuse; 2016 Nov; 42(6):624-632. PubMed ID: 27315522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lifetime prevalence of novel psychoactive substances use among adults in the USA: Sociodemographic, mental health and illicit drug use correlates. Evidence from a population-based survey 2007-2014.
    Neicun J; Yang JC; Shih H; Nadella P; van Kessel R; Negri A; Czabanowska K; Brayne C; Roman-Urrestarazu A
    PLoS One; 2020; 15(10):e0241056. PubMed ID: 33125395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. For what diagnoses are psychotropic medications being prescribed?: a nationally representative survey of physicians.
    Mark TL
    CNS Drugs; 2010 Apr; 24(4):319-26. PubMed ID: 20297856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. I like the old stuff better than the new stuff? Subjective experiences of new psychoactive substances.
    Matthews A; Sutherland R; Peacock A; Van Buskirk J; Whittaker E; Burns L; Bruno R
    Int J Drug Policy; 2017 Feb; 40():44-49. PubMed ID: 27939599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns and correlates of new psychoactive substance use in a sample of Australian high school students.
    Champion KE; Teesson M; Newton NC
    Drug Alcohol Rev; 2016 May; 35(3):338-44. PubMed ID: 26194894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polysubstance use profiles among electronic dance music party attendees in New York City and their relation to use of new psychoactive substances.
    Fernández-Calderón F; Cleland CM; Palamar JJ
    Addict Behav; 2018 Mar; 78():85-93. PubMed ID: 29128711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlates of new psychoactive substance use among a self-selected sample of nightclub attendees in the United States.
    Palamar JJ; Barratt MJ; Ferris JA; Winstock AR
    Am J Addict; 2016 Aug; 25(5):400-7. PubMed ID: 27419383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of the effects of novel psychoactive substances 'legal highs' on people with severe mental illness.
    Gray R; Bressington D; Hughes E; Ivanecka A
    J Psychiatr Ment Health Nurs; 2016 Jun; 23(5):267-81. PubMed ID: 27037639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing self-reported use of new psychoactive substances: The impact of gate questions.
    Palamar JJ; Acosta P; Calderón FF; Sherman S; Cleland CM
    Am J Drug Alcohol Abuse; 2017 Sep; 43(5):609-617. PubMed ID: 28485987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychoactive substances--some new, some old: a scan of the situation in the U.S.
    Maxwell JC
    Drug Alcohol Depend; 2014 Jan; 134():71-77. PubMed ID: 24140401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic cathinones: a new public health problem.
    Karila L; Megarbane B; Cottencin O; Lejoyeux M
    Curr Neuropharmacol; 2015 Jan; 13(1):12-20. PubMed ID: 26074740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to ask about the use of new psychoactive substances to increase the validity of results in self-report prevalence surveys.
    Drapalova E; Belackova V; Cadet-Taïrou A
    Drug Alcohol Rev; 2020 Mar; 39(3):278-286. PubMed ID: 32078202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature.
    Chiappini S; Mosca A; Miuli A; Santovito MC; Orsolini L; Corkery JM; Guirguis A; Pettorruso M; Martinotti G; Di Giannantonio M; Schifano F
    Medicina (Kaunas); 2021 Jun; 57(6):. PubMed ID: 34204131
    [No Abstract]   [Full Text] [Related]  

  • 17. Prevalence of use and acute toxicity associated with the use of NBOMe drugs.
    Wood DM; Sedefov R; Cunningham A; Dargan PI
    Clin Toxicol (Phila); 2015 Feb; 53(2):85-92. PubMed ID: 25658166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical challenges of synthetic cathinones.
    Schifano F; Napoletano F; Arillotta D; Zangani C; Gilgar L; Guirguis A; Corkery JM; Vento A
    Br J Clin Pharmacol; 2020 Mar; 86(3):410-419. PubMed ID: 31674690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New psychoactive substances in Taiwan: The current situation and initiative for rational scheduling.
    Yu WJ; Cottler L; Li JH
    J Food Drug Anal; 2021 Mar; 29(1):168-181. PubMed ID: 35696229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What's New on the Street?: An Update on New Opioids, Psychoactive Drugs, and Synthetic Marijuana.
    Harris-Haman PA
    Crit Care Nurs Clin North Am; 2024 Jun; 36(2):211-221. PubMed ID: 38705689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.